Localized Palmar Vancomycin-Induced Linear IgA Bullous Dermatosis Occurring at Supratherapeutic Levels

Walsh, Sarah N.; Kerchner, Katherine; Sangüeza, Omar P.

doi:10.1001/archdermatol.2009.68

Cited by 19 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in our patient, vancomycin was the most likely culprit, though direct cause was not determined. Although multiple case reports have documented drug exposure as a precipitating factor, formal studies validating the existence of drug-induced LABD are lacking [13]. Vancomycin and phenytoin have both been reported to induce LABD with vancomycin being the pharmacologic agent most frequently reported as a potential inciting factor [13].…”

Section: Discussionmentioning

confidence: 99%

“…Although multiple case reports have documented drug exposure as a precipitating factor, formal studies validating the existence of drug-induced LABD are lacking [13]. Vancomycin and phenytoin have both been reported to induce LABD with vancomycin being the pharmacologic agent most frequently reported as a potential inciting factor [13]. Vancomycin has also been reported to cause localized LABD confined to the palms at supratherapeutic levels [14].…”

Section: Discussionmentioning

confidence: 99%

“…Also, drug-induced LABD had a more severe presentation than the spontaneous form with Nikolsky sign and large erosions mimicking toxic epidermal necrolysis and other bullous diseases making Nikolsky sign insignificant. DIF assay was recommended for all patients with Nikolsky sign and large erosions [13].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Vancomycin-induced bullous dermatosis

Kim¹,

Baquerizo²,

Srivastava³

et al. 2016

IJCRI

View full text Add to dashboard Cite

International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties.Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations.IJCRI publishes Review Articles, Case Series, Case Reports, Case in Images, Clinical Images and Letters to Editor. Website: www.ijcasereportsandimages.com Vancomycin-induced bullous dermatosisMartin Minwoo Kim, Katherine Baquerizo, Pranay Srivastava, Deepthi Lankalapalli, Asmat Ullah ABSTRACT Introduction: Linear IgA bullous dermatosis (LABD) is a rare mucocutaneous immune mediated blistering skin disease seen in various countries that have ranged from less than 0.5 to 2.3 cases per million individuals per year. The presentation can be similar to other bullous dermatoses, yet it has distinctive clinicopathologic and immunologic features that allow prompt recognition and treatment with complete resolution. Case Report: A 54-year-old obese Caucasian male with past medical history of atrial fibrillation on warfarin, hypertension, gastroesophageal reflux disease, benign prostatic hyperplasia, and dyslipidemia presented to the emergency department complaining of a generalized blistering rash that initially surrounded the genitalia a week after being discharged from the hospital following a mechanical fall. All medications were reviewed and skin biopsy was taken. He developed the drug-induced variant of LABD to vancomycin with mucosal involvement and compare the resemblance to other autoimmune blistering diseases such as toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome. This case demonstrates complete resolution of the disease with prompt identification of the underlying disease process based on the clinical and immunohistochemistry findings. Conclusion: Linear IgA bullous dermatosis can be difficult to diagnose as it presents similar to other bullous dermatoses. The problem of differential diagnosis coupled with clinicopathologic and immunologic features of LABD are emphasized to recognize this distinct disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vancomycin-induced bullous dermatosis

Kim¹,

Baquerizo²,

Srivastava³

et al. 2016

IJCRI

View full text Add to dashboard Cite

show abstract

“…The diagnostic difficulty of LABD may include a controversial clinical presentation mimicking simply dermatitis, herpes infection, bullous pemphigoid, erythema multiforme, and most significantly toxic epidermal necrolysis [2][3][4][5][6]. Likewise, LABD has been associated with a variety of disease settings; solid and hematological malignancies, infections, autoimmune basis, and drugs [7][8][9][10][11].…”

Section: Journal Of Clinical and Experimental Dermatology Researchmentioning

confidence: 99%

“…Although the etiopathology of LADB is unknown, increasing evidences have suggested an occasional drug exposure in a substantial number of the patients. Among the causative drugs, vancomycin hydrochloride, a glycopeptide antibiotic agent, has frequently been reported [1][2][3][4][5][6], and the rare clinicopathology of the drug-induced LABD can be a noteworthy updating to assist the awareness of the underlying disease cause. We herein report the first case of vancomycin-induced LABD presenting as erythroderma, whose in vivo IgA deposit reacted with both laminin-332 and type VII collagen.…”

Section: Introductionmentioning

confidence: 99%

Possible Dual Immunoreactivity for Laminin-332 and Type VII Collagen in a Case with Vancomycin-Induced Linear Iga Bullous Dermatosis Manifesting as Erythroderma

Asoh¹,

Oyama²

2012

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

SummaryWe report a unique case of vancomycin-induced linear IgA bullous dermatosis (LABD) presenting as erythroderma. Direct immunofluorescence showed a linear IgA deposition at the dermal side of the basement membrane zone (BMZ), and double immunostaining using patients' skin as a substrate revealed that the in vivo IgA signal co-localized with laminin-332 and type VII collagen. Our case is the first documentation of vancomycin-induced LABD, in which the pathogenic IgA deposit would concomitantly recognize the two distinct antigens at the dermal BMZ.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2009

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Localized Palmar Vancomycin-Induced Linear IgA Bullous Dermatosis Occurring at Supratherapeutic Levels

Cited by 19 publications

References 5 publications

Vancomycin-induced bullous dermatosis

Vancomycin-induced bullous dermatosis

Possible Dual Immunoreactivity for Laminin-332 and Type VII Collagen in a Case with Vancomycin-Induced Linear Iga Bullous Dermatosis Manifesting as Erythroderma

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About